Theravance Biopharma, Inc.
TBPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TBPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory medicines, with a marketed product YUPELRI and a late-stage pipeline candidate ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH).
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$885.2M
Cash Runway
167.4 moLead Asset
ampreloxetine (Phase 3)Next Catalyst
Phase3_Topline · Jan 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 2 catalysts for Theravance Biopharma, Inc..
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory medicines, with a marketed product YUPELRI and a late-stage pipeline candidate ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH).
- Cash and equivalents of $220.6M as of 2026-06-30, with no long-term debt [sec].
- Total revenue of $20.7M and net loss of -$5.9M for the six months ended 2025-06-30 [sec].
- Marketed product YUPELRI (revefenacin) for COPD, with patent/exclusivity expiry expected in 2039-10-23 [sec_mda].
- Phase 3 topline data for ampreloxetine in nOH expected in 2028-01-01 [sec_mda].
- Received $225M from GSK in June 2025 via a royalty sale agreement on TRELEGY [sec_mda].
What works
- Strong cash position of $220.6M as of 2026-06-30 with no long-term debt provides financial flexibility to fund operations and pipeline development [sec].
- YUPELRI is a marketed product with a long patent/exclusivity runway until 2039-10-23, offering potential for sustained revenue [sec_mda].
- The $225M royalty sale to GSK in June 2025 provides a significant non-dilutive capital infusion [sec_mda].
What to weigh
- The company reported a net loss of -$5.9M for the six months ended 2025-06-30, indicating ongoing operating losses [sec].
- Ampreloxetine is still in Phase 3 development with topline data not expected until 2028-01-01, meaning no near-term revenue from this candidate [sec_mda].
- The company operates in a highly competitive and heavily regulated industry, with risks including clinical trial outcomes and commercial execution [sec].
From the filings
Quoted directly from source documents.
Cash position and no debt
“As of September 30, 2025, we had approximately $332.7 million in cash, cash equivalents, and investments in marketable securities (excluding restricted cash) and no long-term debt.”
SEC MD&A · November 12, 2025
Catalyst timeline
- 2028-01-01 · Phase3_Topline · ampreloxetine — Topline results from a Phase 3 withdrawal study of ampreloxetine for symptomatic neurogenic orthostatic hypotension.
- 2039-10-23 · Patent_Expiry · YUPELRI — Patent/exclusivity expiry for YUPELRI, which could allow generic competition.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Ampreloxetine Phase 3 results may not meet endpoints, delaying or preventing regulatory approval [sec_mda].
- Revenue concentration — YUPELRI is the only marketed product; reliance on a single product for commercial revenue [sec].
- Patent expiry exposure — YUPELRI patent expires in 2039-10-23, opening to generic competition [sec_mda].
- Regulatory and competitive landscape — Operates in a heavily regulated, competitive industry with rapid changes [sec].
What to watch
- Phase 3 topline data for ampreloxetine in nOH expected in 2028-01-01 [sec_mda].
- YUPELRI sales performance and market share in the COPD space [sec_mda].
- Any new collaboration or licensing deals to expand pipeline or revenue [sec].
- Cash burn rate and whether the company remains on track to fund operations beyond the next twelve months [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Theravance Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Theravance Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
167.4 months
D/E 0.62 · 0% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~489d
0 buys · 9 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$625.6M
| Holder | Shares | Value |
|---|---|---|
| weiss asset management lp | 7,457,060 | $121.0M |
| newtyn management, llc | 4,841,629 | $78.6M |
| blackrock, inc. | 4,296,290 | $69.7M |
| vanguard capital management llc | 3,567,506 | $57.9M |
| state street corp | 1,297,323 | $21.1M |
| two sigma investments, lp | 1,258,497 | $20.4M |
| geode capital management, llc | 1,137,462 | $18.5M |
| dimensional fund advisors lp | 983,615 | $16.0M |
| d. e. shaw & co., inc. | 954,042 | $15.5M |
| ubs group ag | 764,105 | $12.4M |
Showing top 10 of 170 institutional holders of Theravance Biopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 16.3%
- Days to cover
- 5.5
- Shares short
- 5,262,895
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TBPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Theravance Biopharma, Inc.?
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory medicines, with a marketed product YUPELRI and a late-stage pipeline candidate ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH).
What is Theravance Biopharma, Inc.'s lead drug candidate?
Theravance Biopharma, Inc.'s most advanced tracked candidate is ampreloxetine (Phase 3) for Symptomatic Neurogenic Orthostatic Hypotension.
What is Theravance Biopharma, Inc.'s next catalyst?
Theravance Biopharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th" — expected January 1, 2028.
Who is the CEO of Theravance Biopharma, Inc.?
Mr. Rick E. Winningham M.B.A. is the chief executive officer of Theravance Biopharma, Inc. (TBPH).
Where is Theravance Biopharma, Inc. headquartered?
Theravance Biopharma, Inc. (TBPH) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.